title: [Dyspnea in left-sided heart disease].
abstract: Shortness of breath (dyspnea) is a common symptom in left-sided heart disease but clinically, patient symptoms show a high variability. Echocardiography is the mainstay for evaluating whether left-sided heart disease is the cause of dyspnea. If left-sided heart failure is diagnosed, this symptom complex must then be subjected to further etiological evaluation. Hypertensive, ischemic and valvular heart diseases are common, as well as atrial fibrillation. If the patient does not have angina pectoris, testing for ischemic heart disease should be done non-invasively by coronary computed tomography or testing for regional myocardial ischemia. Coronary revascularization is indicated only when a prognostically relevant ischemia of more than 10 % of the left ventricle is diagnosed. Diuretics are important for the relief of dyspnea but do not improve the prognosis of patients. In patients with reduced left ventricular function, combination therapy with angiotensin-converting enzyme (ACE) inhibitors, beta blockers and aldosterone antagonists improve the symptoms and prognosis. For treatment of heart failure with preserved ejection fraction evidence-based measures are still lacking. In this case the recommended therapy consists of optimal treatment of comorbidities, regulation of heart rate and blood pressure and participation in structured exercise programs. Angiotensin receptor blockers and aldosterone antagonists can be given in patients with more severe symptoms even though the available data are very sparse.
authors.affiliation: Praxisklinik Herz und Gefäße, Forststr. 3, 01099, Dresden, Deutschland, gregor.simonis@praxisklinik-dresden.de.
authors.forename: G
authors.initials: G
authors.lastname: Simonis
authors.forename: J
authors.initials: J
authors.lastname: Stumpf
authors.forename: R
authors.initials: R
authors.lastname: Dörr
authors.forename: C T
authors.initials: CT
authors.lastname: Kadalie
authors.forename: S G
authors.initials: SG
authors.lastname: Spitzer
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002316:Cardiotonic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000379:methods; D004232:Diuretics / Q000627:therapeutic use*; D004417:Dyspnea / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D019317:Evidence-Based Medicine; D005081:Exercise Therapy / Q000379:methods*; D006333:Heart Failure / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002316:Cardiotonic Agents; D004232:Diuretics